Hydroxyurea
- Generic Name
- Hydroxyurea
- Brand Names
- Droxia, Hydrea, Siklos, Xromi
- Drug Type
- Small Molecule
- Chemical Formula
- CH4N2O2
- CAS Number
- 127-07-1
- Unique Ingredient Identifier
- X6Q56QN5QC
- Background
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
- Indication
Hydroxyurea is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in adult and pediatric patients, 2 years of age and older, with sickle cell anemia with recurrent moderate to severe painful crises.
- Associated Conditions
- Chronic Myelogenous Leukemia (CML), Essential Thrombocythemia (ET), Head and Neck Primary Squamous Cell Carcinoma, Hypereosinophilic Syndrome (HES), Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN), Meningiomas, Polycythemia Vera (PV), Sickle Cell Crisis, Vaso-occlusive Crisis
- Associated Therapies
- Chemoradiotherapy, Radiation Therapy
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy
- Conditions
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 140
- Registration Number
- NCT00001074
- Locations
- 🇺🇸
Julio Arroyo, West Columbia, South Carolina, United States
🇺🇸Johns Hopkins Hosp, Baltimore, Maryland, United States
🇺🇸Univ of Colorado Health Sciences Ctr, Denver, Colorado, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Delavirdine Mesylate Plus MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002420
- Locations
- 🇺🇸
Pacific Oaks Med Group, Beverly Hills, California, United States
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00002418
- Locations
- 🇺🇸
Univ of Colorado / Health Science Ctr, Denver, Colorado, United States
🇺🇸Brown Univ School of Medicine, Providence, Rhode Island, United States
🇺🇸AIDS Research Consortium of Atlanta, Atlanta, Georgia, United States
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia
- Conditions
- Interventions
- First Posted Date
- 2000-10-13
- Last Posted Date
- 2020-08-19
- Target Recruit Count
- 193
- Registration Number
- NCT00006400
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Howard University, Washington, District of Columbia, United States
🇺🇸Emory University School of Medicine, Atlanta, Georgia, United States
Hydroxyurea to Treat Beta-Thalassemia (Cooley's Anemia)
- Conditions
- First Posted Date
- 2000-01-19
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 100
- Registration Number
- NCT00001958
- Locations
- 🇺🇸
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States
Hydroxyurea for the Treatment of Patients With Sickle Cell Anemia
- Conditions
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2019-12-16
- Target Recruit Count
- 41
- Registration Number
- NCT00001197
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG)
- Conditions
Multicenter Study of Hydroxyurea in Patients With Sickle Cell Anemia (MSH)
- Conditions
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia
- Conditions
- First Posted Date
- 1999-10-19
- Last Posted Date
- 2015-03-25
- Lead Sponsor
- University of North Carolina
- Target Recruit Count
- 20
- Registration Number
- NCT00004492
- Locations
- 🇺🇸
University of North Carolina School of Medicine, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.